By RTT News, December 12, 2014, 07:18:00 AM EDT

(RTTNews.com) - Alnylam Pharmaceuticals, Inc. ( ALNY ) announced its pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas, or STArs: Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease. The company said its strategic therapeutic areas will remain focused on liver-expressed and genetically validated or pathogen-derived disease targets, with biomarkers for assessment of clinical activity early in Phase 1 trials.

In Genetic Medicine STAr, Alnylam said it is advancing a broad pipeline of RNAi therapeutics for rare diseases. Across the Genetic Medicine STAr, Alnylam plans on commercializing its products through direct marketing and sales in the U.S. and EU, while leveraging its landmark partnership with Genzyme, a Sanofi company, for commercialization in the rest-of-world.

In Cardio-metabolic Disease STAr, Alnylam is advancing pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in dyslipidemias, hypertension, non-alcoholic steatohepatitis, and type 2 diabetes. The company intends to seek strategic partnership opportunities for programs in Cardio-metabolic Disease STAr, while retaining significant product commercialization rights in the U.S. and EU.

In Hepatic Infectious Disease STAr, Alnylam is advancing a pipeline of RNAi therapeutics that address major global health challenges, including hepatitis B virus and hepatitis D virus infections, amongst other hepatic infectious disease opportunities. The company intends to seek strategic partnership opportunities for programs in its Hepatic Infectious Disease STAr, while retaining significant product commercialization rights in the U.S. and EU.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

More here:
Alnylam Pharma Announces Pipeline Growth Strategy For RNAi Therapeutics